Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BeiGene's Brukinsa PFS Win Lifts China Biotech Stocks

Bests Imbruvica In CLL

Executive Summary

BeiGene's Brukinsa beats Imbruvica in top-line progression-free survival results from the Phase III head-to-head ALPINE trial in chronic lymphocytic leukemia or small lymphocytic lymphoma, marking the first time a rival BTK inhibitor has bested the same-class standard of care in this setting, and lifting the shares of other Chinese biotechs.

You may also be interested in...



Keeping Track: New Claims For Tukysa, Brukinsa; US FDA Wants More Patients To Support Donanemab, Pediatric Airsupra Bids

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Cancer Drugs And Medicare: Range Of Impacts Expected From IRA Price Reforms

Alkermes discusses oncology drug spin-off, Lilly discloses decision to halt development of a small molecule drug, and AbbVie comments on pending Medicare price negotiation for Imbruvica.

China Approves Two More Home-Grown COVID-19 Antivirals

Top-line results for two newly approved COVID-19 antivirals in China showed roughly 1.5- to two-day cuts in median time to symptom resolution or recovery in mild-to-moderate Omicron patients versus placebo.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC147221

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel